Gain Therapeutics, Inc.
GANX
$3.32
$0.268.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.39M | -18.59M | -20.93M | -20.41M | -21.37M |
| Total Depreciation and Amortization | 39.10K | 37.90K | 38.20K | 37.00K | 39.30K |
| Total Amortization of Deferred Charges | 48.00K | 48.00K | 46.00K | 47.00K | 47.00K |
| Total Other Non-Cash Items | 3.11M | 2.95M | 3.07M | 2.53M | 2.04M |
| Change in Net Operating Assets | -1.11M | -2.90M | -1.34M | -1.08M | -1.84M |
| Cash from Operations | -17.30M | -18.45M | -19.11M | -18.87M | -21.08M |
| Capital Expenditure | -900.00 | -900.00 | -22.40K | -22.40K | -21.50K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.50K | -42.50K | 1.98M | 5.00M | 8.18M |
| Cash from Investing | -43.40K | -43.40K | 1.96M | 4.98M | 8.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -94.20K | -92.30K | -90.20K | -90.90K | -90.70K |
| Issuance of Common Stock | 14.70M | 8.08M | 15.65M | 13.38M | 20.63M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -395.50K | 0.00 | 0.00 | -280.90K | -280.90K |
| Cash from Financing | 14.21M | 7.99M | 15.56M | 13.01M | 20.26M |
| Foreign Exchange rate Adjustments | -104.30K | 271.80K | 24.80K | -527.20K | 436.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.24M | -10.24M | -1.57M | -1.41M | 7.78M |